- Home
- LDP vs NEO Comparison
LDP vs NEO Comparison
Compare LDP & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- NEO
- Stock Information
- Founded
- LDP 2012
- NEO 2001
- Country
- LDP United States
- NEO United States
- Employees
- LDP N/A
- NEO N/A
- Industry
- LDP Finance Companies
- NEO Precision Instruments
- Sector
- LDP Finance
- NEO Health Care
- Exchange
- LDP Nasdaq
- NEO Nasdaq
- Market Cap
- LDP 613.9M
- NEO 709.2M
- IPO Year
- LDP N/A
- NEO 1999
- Fundamental
- Price
- LDP $21.18
- NEO $6.21
- Analyst Decision
- LDP
- NEO Buy
- Analyst Count
- LDP 0
- NEO 8
- Target Price
- LDP N/A
- NEO $12.00
- AVG Volume (30 Days)
- LDP 102.5K
- NEO 3.1M
- Earning Date
- LDP 01-01-0001
- NEO 07-29-2025
- Dividend Yield
- LDP 7.91%
- NEO N/A
- EPS Growth
- LDP N/A
- NEO N/A
- EPS
- LDP N/A
- NEO N/A
- Revenue
- LDP N/A
- NEO $689,189,000.00
- Revenue This Year
- LDP N/A
- NEO $13.83
- Revenue Next Year
- LDP N/A
- NEO $11.35
- P/E Ratio
- LDP N/A
- NEO N/A
- Revenue Growth
- LDP N/A
- NEO 9.70
- 52 Week Low
- LDP $16.16
- NEO $4.72
- 52 Week High
- LDP $20.30
- NEO $19.12
- Technical
- Relative Strength Index (RSI)
- LDP 48.49
- NEO 50.53
- Support Level
- LDP $20.93
- NEO $5.37
- Resistance Level
- LDP $21.55
- NEO $6.34
- Average True Range (ATR)
- LDP 0.16
- NEO 0.39
- MACD
- LDP -0.03
- NEO 0.13
- Stochastic Oscillator
- LDP 37.31
- NEO 91.98
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About NEO NeoGenomics Inc.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.